Showing results (1311-1320 of 1,329) with videos related to

Sort By:
Pageof 133
Journal of Viral Hepatitis|August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1T Oze, N Hiramatsu, T Yakushijin, et al.
Circulation|October 17, 2001
Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin geneT Shindo, Y Kurihara, H Nishimatsu, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2005
A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugsS Nakashima, S Arai, Y Mizuno, et al.
Liver|April 1, 1997
Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose studyY Imai, S Kawata, S Tamura, et al.
Journal of Viral Hepatitis|August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responsesY Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis|April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirinN Harada, N Hiramatsu, T Oze, et al.
Journal of Human Hypertension|June 4, 2010
European Society of Hypertension practice guidelines for home blood pressure monitoringG Parati, G S Stergiou, R Asmar, et al.
Journal of Human Hypertension|January 17, 2014
Ambulatory blood pressure monitoring for risk stratification in obese and non-obese subjects from 10 populationsT W Hansen, L Thijs, Y Li, et al.
Journal of Viral Hepatitis|June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirinT Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirinN Hiramatsu, T Oze, T Yakushijin, et al.
Pageof 133